| Structure |
Chemical Name |
CAS |
MF |
![(2R,3R,4S,5R)-2-(6-aMino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]iMidazol-2-yl)ethyl)cyclobutyl)(isopropyl)aMino)Methyl)tetrahydrofuran-3,4-diol](/CAS/20150408/GIF/1380288-87-8.gif) |
(2R,3R,4S,5R)-2-(6-aMino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]iMidazol-2-yl)ethyl)cyclobutyl)(isopropyl)aMino)Methyl)tetrahydrofuran-3,4-diol |
1380288-87-8 |
C30H42N8O3 |
 |
S)-1-(sec-butyl)-N-((4,6-diMethyl-2-oxo-1,2-dihydropyridin-3-yl)Methyl)-3-Methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxaMide |
1346574-57-9 |
C31H38N6O2 |
 |
UNC 1999 |
1431612-23-5 |
C33H43N7O2 |
 |
Tazemetostat (EPZ-6438) |
1403254-99-8 |
C34H44N4O4 |
 |
EPZ004777 |
1338466-77-5 |
C28H41N7O4 |
 |
UNC 0631 |
1320288-19-4 |
C37H61N7O2 |
 |
GSK 343 |
1346704-33-3 |
C31H39N7O2 |
 |
1-Cyclopentyl-N-((4,6-diMethyl-2-oxo-1,2-dihydropyridin-3-yl)Methyl)-6-(4-(MorpholinoMethyl)phenyl)-1H-indazole-4-carboxaMide |
1396772-26-1 |
C32H37N5O3 |
 |
MI-2 (Menin-MLL Inhibitor) |
1271738-62-5 |
C18H25N5S2 |
 |
MM-102 |
1417329-24-8 |
C35H49F2N7O4 |
 |
SGC0946 |
1561178-17-3 |
C28H40BrN7O4 |
 |
EI1 |
1418308-27-6 |
C23H26N4O2 |
 |
UNC0379 |
1620401-82-2 |
C23H35N5O2 |
![3-Cyclopentene-1,2-diol, 5-(4-aMino-1H-iMidazo[4,5-c]pyridin-1-yl)-3-(hydroxyMethyl)-, (Hydrochloride) (1:1), (1S,2R,5R)-](/CAS/GIF/120964-45-6.gif) |
3-Cyclopentene-1,2-diol, 5-(4-aMino-1H-iMidazo[4,5-c]pyridin-1-yl)-3-(hydroxyMethyl)-, (Hydrochloride) (1:1), (1S,2R,5R)- |
120964-45-6 |
C12H15ClN4O3 |
 |
PFI-2 |
1627676-59-8 |
C23H25F4N3O3S |
 |
BRD4770 |
1374601-40-7 |
C25H23N3O3 |
 |
MI-3 (Menin-MLL Inhibitor) |
1271738-59-0 |
C18H25N5S2 |
 |
BIX 01294 |
1392399-03-9 |
C28H41Cl3N6O2 |
 |
EPZ015666 |
1616391-65-1 |
C20H25N5O3 |